Searched for
ERIS LIFESCIENCES STOCKS
Ipca Laboratories among 5 stocks showing bullish RSI upswingFive Nifty500 stocks, including Leela Palaces, Eris Lifesciences, Indian Bank, Mankind Pharma, and Ipca Laboratories, showed bullish moment...- Dividend alert! Last date to buy Bajaj Auto, GSK Pharma and 10 other stocks for solid payouts. Details hereTwelve companies are set to go ex-dividend on Friday, offering shareholders payouts totaling over Rs 250. Bajaj Auto leads with a Rs 150 pe...
- Dividends, bonus issues: TCS, LIC, Bajaj Auto among 30 stocks turning ex-date this week. Check detailsInvestors must hold shares of these companies in their demat accounts on the record date to be eligible for the respective corporate action...
- Eris Lifesciences among 5 stocks showing bullish RSI upswingFive Nifty500 stocks featured in the RSI Trending Up scan on May 20 after gaining over 5%. The RSI moved above the 50 mark from lower level...
- Crorepati investors splurge $1 billion to buy these 10 stocks. Should you follow the smart money?Wealthy investors are making significant moves, pouring over $1 billion into ten select stocks. This concentrated buying occurs even as the...
- Dr. Reddy’s among 4 stocks showing bullish RSI upswingFour stocks from the Nifty500 universe that gained over 3% were identified using the RSI Trending Up scan on April 23. The signal occurs wh...
- Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in IndiaShares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco...
- Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore dealEris Lifesciences is set to fully acquire its injectable unit, Swiss Parenterals. The deal involves a share swap valued at Rs 423.3 crore. ...
- Buy Eris Lifesciences, target price Rs 1100: Prabhudas LilladherEris Lifesciences Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2023.
- Neutral on Eris Lifesciences, target price Rs 930: Motilal OswalEris Lifesciences Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2023.
- Buy Eris Lifesciences, target price Rs 1070: HDFC SecuritiesEris Lifesciences Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2023.
- Buy Eris Lifesciences, target price Rs 1050: Prabhudas LilladherEris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 12633.84 Crore) operating in Pharmac...
- Buy Eris Lifesciences, target price Rs 710: Motilal Oswal Financial ServicesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 7871.82 Crore) operating in Pharmaceutica...
- Buy Eris Lifesciences, target price Rs 780: Motilal Oswal Financial ServicesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceutica...
- Buy Eris Lifesciences, target price Rs 825: Prabhudas LilladherEris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 9395.71 Crore) operating in Pharmace...
- Buy Eris Lifesciences, target price Rs 850: Prabhudas LilladherEris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8921.10 Crore) operating in Pharmace...
- Eris Lifesciences Q3 Results: Profit rises to Rs 101 croreRevenue stood at Rs 332 crore in the third quarter of the current fiscal as compared to Rs 310 crore in the year-ago period, Eris Lifescien...
- Buy Eris Lifesciences, target price Rs 880: ICICI DirectEris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 10371.61 Crore) operating in Pharmac...
- Buy Eris Lifesciences, target price Rs 660: Yes SecuritiesEris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8217.45 Crore) operating in Pharmace...
- Buy Eris Lifesciences, target price Rs 690: Haitong SecuritiesThe brokerage values Eris at a 20 per cent premium to its mid-cap peers.
Load More
